Wednesday, December 26, 2018 2:59:19 PM
HC Wainwright Bullish On Corbus Therapeutics' Cystic Fibrosis Opportunity
Priya Nigam , Benzinga Staff Writer December 26, 2018 11:50am
Corbus Pharmaceuticals Holdings Inc CRBP 5.71% has Phase 3 trials ongoing for its lead compound lenabasum in systemic sclerosis and dermatomyositis, and Phase 2 trials for cystic fibrosis and systemic lupus erythematosus.
With cannabinoid receptor type 2 being a critical component of resolution following inflammation, there could be “significant readthrough from one indication to the next,” according to H.C. Wainwright.
The Analyst
Analyst Andrew Fein initiated coverage of Corbus Pharmaceuticals with a Buy rating and $24 price target.
The Thesis
Although success in systemic sclerosis or dermatomyositis alone may be insufficient to lend upside to Corbus Pharmaceuticals’ shares, there is potential in lenabasum’s ability to address inflammation in cystic fibrosis, Fein said in the Wednesday initiation note.
Cystic fibrosis patients experience chronic inflammation that results in a decline in lung function, and the disease is strongly associated with more frequent pulmonary exacerbations and morbidity.
While Vertex Pharmaceuticals Incorporated
VRTX 4.05%'s triple therapies may make modulator therapy available for nearly 90 percent of those with a CF mutation, modulators of the cystic fibrosis transmembrane conductance regulator are unlikely to fully reverse the structural damage in CF patients, the analyst said.
A need exists for anti-inflammatory therapy in the cystic fibrosis space, Fein said, adding that addressing the resolution phase could offer a new approach. Lenabasum provides "the most advanced agent to target resolution," he said.
https://www.benzinga.com/analyst-ratings/analyst-color/18/12/12899545/hc-wainwright-bullish-on-corbus-therapeutics-cystic-fib
Recent CRBP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 08:52:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:48:47 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:45:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 12:15:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:42:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:38:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 12:15:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:58:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 01:21:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/14/2024 09:25:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:32:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:30:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:29:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:28:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:26:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 11:08:54 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/31/2024 08:39:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 09:00:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 08:59:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 08:58:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 08:54:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 08:53:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/08/2024 08:03:35 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM